Louisiana State Employees Retirement System Makes New $784,000 Investment in Enovis Co. (NYSE:ENOV)

Louisiana State Employees Retirement System acquired a new stake in Enovis Co. (NYSE:ENOV - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 14,000 shares of the company's stock, valued at approximately $784,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Invesco Ltd. boosted its position in Enovis by 116.2% during the third quarter. Invesco Ltd. now owns 472,713 shares of the company's stock worth $24,926,000 after purchasing an additional 254,097 shares during the period. Diamond Hill Capital Management Inc. boosted its position in Enovis by 9.9% during the third quarter. Diamond Hill Capital Management Inc. now owns 2,429,173 shares of the company's stock worth $128,090,000 after purchasing an additional 219,659 shares during the period. DAVENPORT & Co LLC boosted its position in Enovis by 12.6% during the fourth quarter. DAVENPORT & Co LLC now owns 1,879,425 shares of the company's stock worth $105,920,000 after purchasing an additional 210,358 shares during the period. First Eagle Investment Management LLC boosted its position in Enovis by 13,924.1% during the third quarter. First Eagle Investment Management LLC now owns 166,746 shares of the company's stock worth $8,793,000 after purchasing an additional 165,557 shares during the period. Finally, Lawson Kroeker Investment Management Inc. NE bought a new position in Enovis during the fourth quarter worth $7,013,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have commented on ENOV. Wells Fargo & Company lifted their price objective on shares of Enovis from $73.00 to $79.00 and gave the stock an "overweight" rating in a research report on Friday, February 23rd. UBS Group assumed coverage on shares of Enovis in a research report on Monday, January 22nd. They issued a "buy" rating and a $75.00 target price for the company. Needham & Company LLC reissued a "buy" rating and issued a $82.00 target price on shares of Enovis in a research report on Wednesday, April 10th. William Blair assumed coverage on shares of Enovis in a research report on Wednesday, January 3rd. They issued an "outperform" rating for the company. Finally, Canaccord Genuity Group boosted their target price on shares of Enovis from $73.00 to $75.00 and gave the company a "buy" rating in a research report on Friday, February 23rd. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $75.43.

Enovis Trading Up 0.3 %

Shares of Enovis stock traded up $0.16 on Friday, hitting $55.26. The stock had a trading volume of 304,173 shares, compared to its average volume of 444,742. The stock has a 50 day moving average of $59.87 and a 200 day moving average of $55.52. Enovis Co. has a twelve month low of $43.04 and a twelve month high of $66.14. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.16 and a current ratio of 2.43. The firm has a market capitalization of $3.03 billion, a P/E ratio of -90.59 and a beta of 1.97.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Thursday, February 22nd. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.76 by $0.03. Enovis had a positive return on equity of 3.84% and a negative net margin of 1.95%. The company had revenue of $455.00 million during the quarter, compared to the consensus estimate of $444.34 million. During the same quarter in the prior year, the firm posted $0.72 earnings per share. The firm's revenue was up 11.2% compared to the same quarter last year. Sell-side analysts expect that Enovis Co. will post 2.58 earnings per share for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.